HemaCare (HEMA) Stock Price, News & Analysis

Company Overview

HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.

In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers. The company maintains quality systems compliant with current Good Manufacturing Practices (cGMP) and enforces rigorous donor eligibility criteria to ensure reproducibility and traceability. HemaCare’s scientific team collaborates closely with clients to optimize cell selection, viability and functionality for specific assay requirements.

Headquartered in Southern California, HemaCare sources human cell products through a network of accredited collection sites across North America and Europe. The company’s distribution infrastructure is designed to deliver temperature-controlled shipments to research laboratories and contract research organizations worldwide. With a focus on reliable supply, regulatory compliance and scientific support, HemaCare aims to enable translational breakthroughs and advance innovation in cell-based therapies and diagnostics.

Key Stats

• Today's Range: $25.31 to $25.31
• 50-Day Range: $25.31 to $25.31
• 52-Week Range: $8.62 to $26.23
• Volume: 5,400 shs
• Average Volume: 39,950 shs
• Market Capitalization: $346.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEMA Stock Analysis - Frequently Asked Questions

How have HEMA shares performed this year?

HemaCare's stock was trading at $25.31 at the beginning of the year. Since then, HEMA stock has increased by 0.0% and is now trading at $25.31.

How do I buy shares of HemaCare?

Shares of HEMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HemaCare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HemaCare investors own include First Majestic Silver (AG), Warner Bros. Discovery (DISCA), Cognizant Technology Solutions (CTSH), Canadian Solar (CSIQ), Conduent (CNDT), CMC Materials (CCMP) and Athenex (ATNX).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Miscellaneous Health & Allied Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HEMA
• CIK: 801748
• Web: www.hemagen.com
• Phone: 818-226-1968
• Fax: N/A
• Employees: N/A
• Year Founded: 1978

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 13,691,000
• Free Float: N/A
• Market Cap: $346.52 million
• Optionable: Not Optionable
• Beta: 1.47